Industry News
Leukemia Drug Sprycel (Dasatinib) Has Risk Of Pulmonary Arterial Hypertension, Warns FDA
Oct 11, 2011
Sprycel (dasatinib), a leukemia medication raises the risk of developing pulmonary arterial hypertension, the US Food and Drug Administration (FDA) announced today in a Drug Safety Communication. The FDA says doctors should check patients for signs and symptoms of underlying cardiopulmonary disease before considering prescribing Sprycel - they should also evaluate patients during treatment... Read More
Chronic Lymphocytic Leukemia Patients' Lives Extended By New Combination Treatment
Oct 11, 2011
According to an investigation published Online First in The Lancet Oncology, for individuals who have relapsed with the most prevalent type of leukemia, chronic lymphocytic leukemia (CLL), a novel, less toxic, treatment that combines the chemotherapy drug fludarabine and the monoclonal antibody alemtuzumab, considerably increases progression free survival (PFS) and extends the ... Read More
Novel Technique Uses RNA Interference To Block Inflammation
Oct 10, 2011
Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions... Read More
To Slow Rates Of HIV And HPV Transmission In South Africa, Earlier Circumcision In Males May Be Effective Intervention
Oct 10, 2011
According to Anna R. Giuliano, Ph.D., program leader in cancer epidemiology at Moffitt Cancer Center in Tampa, Fla., and colleagues in the Netherlands, earlier circumcision of males in South Africa may be a positive step in slowing the spread of both HIV and the human papillomavirus (HPV)... Read More
Millennium Provides Update On SNDA For VELCADE In Relapsed Follicular Lymphoma
Oct 08, 2011
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) announced that it is withdrawing the supplemental new drug application (sNDA) for the use of VELCADE® (bortezomib) for Injection in combination with rituximab in patients with relapsed follicular lymphoma... Read More
Women's Ability To Track The Signs Of Ovarian Cancer Improved By New App
Oct 07, 2011
Today the Ovarian Cancer National Alliance have released a free app designed to help women learn more about the signs, risks, and symptoms of ovarian cancer, the app also tells you whether you should go and see a doctor... Read More
The Success Of Certain Cancer Therapies Can Be Predicted By Novel Stanford Math Formula
Oct 07, 2011
Carefully tracking the rate of response of human lung tumors during the first weeks of treatment can predict which cancers will undergo sustained regression, suggests a new study by researchers at the Stanford University School of Medicine... Read More
Study Shows Dramatic Rise In Incidence Of Oral Cancer Type Linked To HPV
Oct 04, 2011
A new study of oropharyngeal cancer suggests that dramatic increases in U.S. incidence of the cancer and survival since 1984 can be attributed to infection with the human papillomavirus (HPV)... Read More
Combination HPV Diagnostic Test For Head And Neck Cancer Outperformed Other Tests
Oct 04, 2011
Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive from HPV16, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research... Read More
Including HPV Test In Cervical Screenings Saves 3,500 Women From Pointless Tests
Sep 30, 2011
According to a new study published in the British Journal of Cancer, including testing for the human papillomavirus (HPV) in cervical screenings reduces over a third of further pointless tests for women. The results are from the primary assessment, led by The Institute of Cancer Research, of the 'Sentinel sites' project, which aims to make HPV testing part of routine cervical screening... Read More
Previous Page Next Page